geneType™ for Atrial Fibrillation (AF) integrates clinical and genetic risk factors.
With this one test, geneType™ integrates clinical risk factors to deliver an improved view of your patient’s AF risk in a single risk score.
There are many strategies to proactively manage your patient’s risk of stroke. Understanding and managing your patients’ AF risk is one of them.
Be proactive with your patient and manage their risk before symptoms present.
With geneType™, you can incorporate an additional risk factor, polygenic risk, that looks at underlying common genetic markers associated with AF.
Let geneType™ help inform your decision-making discussions.
Our reports are structured to make the results easy to interpret and communicate to a patient.
The geneType™ for Atrial Fibrillation report includes:
The geneType™ patient
Want to look beyond the obvious risk factors?
AF risk prediction models, like the Framingham, perform well in many adults. But some of your patients would benefit from the identification of the baseline risk that geneType™ can uncover.
geneType™ allows you to integrate the standard clinical factors with your patient’s polygenic risk to deliver a single 10-year risk score.
Register as a provider; our team will provide clinical education and other resources as needed.
We will send kits to your clinic to have on hand.
Discuss geneType™ with your patient.
Would geneType™ help them qualify for additional risk reduction strategies?
Complete the Test Requisition form, collect a saliva sample from the patient with the collection kit provided and return both to Rhythm.
You will have the option to use a paper requisition, or a secure, compliant portal to complete the ordering process.
Leave the rest to us.
We will notify you when your patient’s results are ready.
You will have the option to request a consult with a genetic counsellor, whether to review your patient’s results and/or to follow-up with your patient, as needed.
If your question is not shown here, please Contact us directly.
No. At this time geneType™ is a self-pay test. However, your patient may use FSA/HSA to pay for the test.
This test does not incorporate all possible risk factors for atrial fibrillation into the risk prediction model; however it incorporates the most significant. Test results should be interpreted in the context of the patient’s full clinical and family history.
No.
Even though there are certain coronary artery disease risk factors specific to women, like preeclampsia or gestational diabetes, these factors are not currently incorporated into the model. A woman’s age is incorporated into the model and indirectly accounts for post-menopausal changes associated with increased risk of developing coronary artery disease.
The benefits of geneType™ are two-fold.
First, we incorporate a novel risk factor based on your patient’s underlying genetic markers. There is no other way to identify this baseline level of genetic risk outside of geneType™.
Second, not only do we incorporate this genetic marker, but we combine it with other clinical risk factors and specifically calibrate the model to the general population. When we compare calibration with traditional clinical risk assessment, geneType™ is better calibrated, meaning it can provide more trustworthy risk prediction.
Yes.
While there are direct-to-consumer companies out there that provide random lists of genetic markers that are associated with atrial fibrillation, there are no checks and balances associated with the results they provide. Most of the markers they pull from peer-reviewed publications without cross validating the markers. And more importantly, geneType™ goes through rigorous statistical validation of the genetic component prior to integrating it into the full model. The fully integrated geneType™ model is then validated separately.
*Patient eligibility dependent on personal medical history, age and sex
The Multi-Risk suite of tests is for adults 40-85 years of age. At maximum, a woman would be eligible for eight diseases in the panel; a man would be eligible for seven. Starting at age 30, a patient may qualify for geneType’s™ cancer risk assessments only.
The first step is to trial geneType™ at your practice.
Accredited For Compliance With NPAAC Standards And ISO 15189